[1]
|
A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients
Frontiers in Molecular Biosciences,
2024
DOI:10.3389/fmolb.2023.1248742
|
|
|
[2]
|
Protection of Iron-Induced Oxidative Damage in Neuroblastoma (SH-SY5Y) Cells by Combination of 1-(N-Acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one and Green Tea Extract
Bioinorganic Chemistry and Applications,
2021
DOI:10.1155/2021/5539666
|
|
|
[3]
|
Polymeric nanocarriers for the treatment of systemic iron overload
Molecular and Cellular Therapies,
2015
DOI:10.1186/s40591-015-0039-1
|
|
|
[4]
|
Recent Developments Centered on Orally Active Iron Chelators
Thalassemia Reports,
2014
DOI:10.4081/thal.2014.2261
|
|
|
[5]
|
Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone
Experimental and Toxicologic Pathology,
2014
DOI:10.1016/j.etp.2014.03.002
|
|
|
[6]
|
Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice
Asian Pacific Journal of Tropical Medicine,
2014
DOI:10.1016/S1995-7645(14)60223-6
|
|
|
[7]
|
Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β-thalassemic mice
Asian Pacific Journal of Tropical Biomedicine,
2014
DOI:10.12980/APJTB.4.2014APJTB-2014-0155
|
|
|